Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer

NICE technology appraisal guidance [TA107] Published date:

NICE guideline CG80 Early and locally advanced breast cancer, (published in February 2009) updates the recommendations contained in this appraisal.

  • Correction

    It has been brought to our attention that this guidance contained an error in section 1.3, where it stated that:

    ‘Cardiac functional assessments should be repeated every 3 months during trastuzumab treatment. If the LVEF drops by 10% from baseline and to below 50% then trastuzumab treatment should be suspended…?

    This has now been amended so that it follows more closely the SPC for trastuzumab, as follows:

    ‘Cardiac functional assessments should be repeated every 3 months during trastuzumab treatment. If the LVEF drops by 10 percentage (ejection) points or more from baseline and to below 50% then trastuzumab treatment should be suspended…?

     

    Update to guidance

      NICE and the Department of Health are currently reviewing the future position on updating technology appraisals within clinical guidelines, with particular reference to implications for the funding direction on technology appraisals. In the meantime, the technology appraisal guidance remains available and should continue to be followed. The statutory funding direction remains in place for the recommendations contained in the technology appraisal guidance.

  • Get involved